Pharming Group N.V. (PHAR)
| Market Cap | 1.17B |
| Revenue (ttm) | 376.13M |
| Net Income (ttm) | 2.85M |
| Shares Out | 701.68M |
| EPS (ttm) | 0.00 |
| PE Ratio | 411.03 |
| Forward PE | 42.77 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,414 |
| Open | 16.41 |
| Previous Close | 16.92 |
| Day's Range | 16.41 - 16.55 |
| 52-Week Range | 8.40 - 21.34 |
| Beta | 0.12 |
| Analysts | Strong Buy |
| Price Target | 38.33 (+132.87%) |
| Earnings Date | May 7, 2026 |
About PHAR
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also dev... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for PHAR stock is "Strong Buy." The 12-month stock price target is $38.33, which is an increase of 132.87% from the latest price.
News
Pharming Group to report first quarter 2026 financial results and provide business update on May 7
Leiden, the Netherlands, April 23, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial r...
Pharming Group announces the 2026 Annual General Meeting of Shareholders
Pharming Group N.V. 2026 Annual General Meeting to be be held on Thursday May 28, 2026, at 14:00 CET. Meeting documents available on website Pharming.com.
Pharming Group Transcript: 25th Annual Needham Virtual Healthcare Conference
The company reported strong 2025 revenue growth and set 2026 guidance for continued expansion, driven by RUCONEST and Joenja. Key pipeline milestones include phase II readouts for Joenja in higher prevalent PIDs and pivotal data for napazimone, supporting a strategy to scale in rare diseases.
Pharming Group to participate in April investor conferences
Pharming announced that management will participate in investor conferences Needham Virtual Healthcare and Kempen Life Sciences Conferences in April 2026.
Pharming Group announces the filing of its 2025 Annual Report and Form 20-F
Leiden, the Netherlands, April 2, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced the filing of its Annual Report for the year ended ...
Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older
If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) , a rare primary immunodeficienc...
Pharming Group's Leniolisib Gets Japan Approval To Treat APDS Patients Aged 4 Years And Older
(RTTNews) - Dutch biopharmaceutical company Pharming Group N.V. (PHAR, PHGUF,, PHARM.AS) announced Tuesday that Japan's Ministry of Health, Labour and Welfare or MHLW has approved Joenja (leniolisib),...
Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older
Leiden, the Netherlands, March 24, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced that Japan's Ministry of Health, Labour and Welfare ...
Pharming Group Earnings Call Transcript: Q4 2025
2025 saw 27% revenue growth, a return to operating profitability, and strong cash flow, driven by robust RUCONEST and Joenja performance. 2026 guidance anticipates 8–13% revenue growth, with Joenja's U.S. market as the main growth driver and continued disciplined capital allocation.
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR). Such investors are advise...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR).
Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12
Pharming to report 4th quarter full year 2025 financial results & provide a business update on March 12, 2026 & host conference call 13:30 CET/08:30 EDT.
Pharming Group Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Strong 2025 sales growth was driven by RUCONEST and Joenja, with continued expansion of the rare disease pipeline. Financial guidance for 2026 projects 8–13% revenue growth, supported by disciplined cost management and increased R&D investment.
Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Pharming to attend and present at Oppenheimer 36th Annual Healthcare Life Sciences Conference. CEO & CMO to present on February 25 at 12:40pm ET/18:40 CET.
Pharming Group Transcript: Investor Day 2026
2025 saw 27% revenue growth, with 2026 guidance of $405–$425 million and increased R&D investment. Key pipeline programs leniolisib and napazimone are advancing, with pivotal data readouts expected in the next 18 months, targeting significant unmet needs in rare diseases.
Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS
Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) t...
Pharming Group reports preliminary 2025 revenues and announces Investor Day
Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full ye...
Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit
Pharming to participate in Oppenheimer Movers in Rare Disease Summit on Dec 11 in NYC. Chief Medical Officer Anurag Relan in fireside chat at 1:50 PM ET.
Pharming Group Transcript: Jefferies London Healthcare Conference 2025
The company is experiencing strong growth from its two main assets, RUCONEST and Joenja, with strategic focus on high-value pipeline expansion and disciplined capital allocation. Recent moves include exiting non-core markets, acquiring KL1333, and preparing for new product launches in Europe and Japan.
Pharming Group Earnings Call Transcript: Q3 2025
Q3 2025 saw 30% revenue growth and a quadrupled operating profit, driven by Ruconest and Joenja. Full-year guidance was raised, with strong cash flow and disciplined capital allocation supporting pipeline and international expansion.
Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London
Leiden, the Netherlands, October 30, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the Jefferies Global Health...
Pharming Group to report third quarter 2025 financial results and provide business update on November 6
Pharming to report third quarter 2025 financial results and provide a business update on November 6, 2025, and host conference call at 13:30 CET/07:30 ET.
Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
Pharming announces 12 abstracts have been accepted for presentation at 2025 ACAAI Annual Scientific meeting being held in Orlando, Florida on November 6-10
Pharming Group provides update on previously announced G&A expense reduction plan
Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to acc...